Fig. 1From: Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virusUnivariate sensitivity analysis. DCV daclatasvir, RBV ribavirin, SOF sofosbuvirBack to article page